BIEL’s Fastest Path to Success 1. Hit $400K in
Post# of 8682
(Total Views: 389)
Posted On: 09/12/2025 4:21:21 PM
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor: If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Valuation Scenarios (Conventional Multiples)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0005).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor announcement goes viral.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100)..
.10 PPS: $25M profit, P/E = 100.
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Why BIEL Is Easy to Analyze
Q3 2021: Profitable with $414K revenue (including COVID relief).
Operating costs are ultra-low. Rev's of just $1.5M/year or $400K/quarter likely secures profitability.
PPS could rise by .01 for every $2.5M in annual revenue.
$40M tax-loss carryforward = first $40M in profits are tax-free.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
ActiPatch as a Wellness Powerhouse
Off-label success: menstrual pain, migraines, neuropathy, RLS, opioid reduction, bladder issues.
Emerging potential in prostate health (BPH symptom relief via PEMF/PSWT).
Insider Confidence = Market Signal
Insider loans function like insider buying—without toxic dilution.
BIEL’s insider investment-to-market cap ratio is unmatched.
Technicals Are Primed
50 DMA = .0002
200 DMA = .0002
Golden Cross = .0003
Blue Sky Breakout = .0005
Technicals attract chartists. Fundamentals (news, PR) will follow. With Fed rate cuts ahead, OTC stocks like BIEL are poised to run like 2021.
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor: If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Valuation Scenarios (Conventional Multiples)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0005).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor announcement goes viral.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100)..
.10 PPS: $25M profit, P/E = 100.
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Why BIEL Is Easy to Analyze
Q3 2021: Profitable with $414K revenue (including COVID relief).
Operating costs are ultra-low. Rev's of just $1.5M/year or $400K/quarter likely secures profitability.
PPS could rise by .01 for every $2.5M in annual revenue.
$40M tax-loss carryforward = first $40M in profits are tax-free.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
ActiPatch as a Wellness Powerhouse
Off-label success: menstrual pain, migraines, neuropathy, RLS, opioid reduction, bladder issues.
Emerging potential in prostate health (BPH symptom relief via PEMF/PSWT).
Insider Confidence = Market Signal
Insider loans function like insider buying—without toxic dilution.
BIEL’s insider investment-to-market cap ratio is unmatched.
Technicals Are Primed
50 DMA = .0002
200 DMA = .0002
Golden Cross = .0003
Blue Sky Breakout = .0005
Technicals attract chartists. Fundamentals (news, PR) will follow. With Fed rate cuts ahead, OTC stocks like BIEL are poised to run like 2021.
(1)
(0)